Q3 2021 Immunovia AB (publ) Earnings Call Transcript
Welcome to the Immunovia Audiocast with Teleconference Q3, 2021. (Operator Instructions) Today, I am pleased to present CEO, Patrik Dahlen. Please begin your meeting.
()-
Good afternoon, everyone. Thank you for joining us today, and thank you for your continued interest in Immunovia. My name is Patrik Dahlen, I am the CEO of Immunovia, and I will be presenting the quarter 3 2021 results for Immunovia. We have now passed a pivotal milestone in the company's history. Immunovia, Inc. has launched IMMray PanCan-d, as a laboratory developed test in the United States. And we have tested the first commercial patient samples with IMMray PanCan-d in our laboratory in Marlborough, Massachusetts, U.S. This is a major achievement for all of us here at Immunovia and provides an opportunity for persons in a high-risk group of familiar and hereditary risk group to access the first blood test for early detection of pancreatic cancer.
Next page, please, Page 2. Here, you can read our disclaimers and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
